Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences Opens New US Office

NEW YORK, Feb. 7-Oxford GlycoSciences has opened a new specialty biopharmaceutical headquarters in the United States, the company said today.


The new facility is located in Bridgewater, NJ.


It will be run by Don DeGolyer, Oxford GlycoSciences' new president of global therapeutics. DeGolyer will lead the company's research into specialty biopharmaceuticals, both in the US and internationally.


The New Jersey office will house the company's commercial team, lead by vice president of global marketing Lou Ferrari.


Oxford GlycoScience's drug development focuses on treatments for fungal infections, cancer, Gaucher disease and Fabry's disease.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.